Harnessing CD1d-restricted T cells toward antitumor immunity in humans

Annals of the New York Academy of Sciences

Volumn 1174, Issue , 2009, Pages 61-67

  Neparidze, Natalia ^a   Dhodapkar, Madhav V ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; CD1d; Lipid antigens; Myeloma; Natural killer T cells

Indexed keywords

CD1D ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; LENALIDOMIDE; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR BETA CHAIN; THALIDOMIDE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; CD1D PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONFERENCE PAPER; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATION; MICROORGANISM; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER T CELL; NONHUMAN; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; ARTICLE; EXPERIMENTAL NEOPLASM; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM;

MUS;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD1D; DENDRITIC CELLS; HUMANS; IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; MICE; MULTIPLE MYELOMA; NATURAL KILLER T-CELLS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 70350459318     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04931.x     Document Type: Conference Paper

References (43)

1. Godfrey, D.I. & M. Kronenberg. 2004. Going both ways : immune regulation via CD1 d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
2. Brigl, M. & M.B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890. (Pubitemid 38680443)
3. Bendelac, A. et al. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15: 535-562. (Pubitemid 27169416)
4. Van Kaer, L. 2007. NKT cells: T lymphocytes with innate effector functions. Curr. Opm. Immunol. 19: 354-364. (Pubitemid 46687006)
5. + thymocytes selected by MHC class I molecules. Science 2631 1774-1778.
6. Bendelac, A., P.B. Savage & L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
7. Crowe, N.Y. et al. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
8. Fujii, S. et al. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279. (Pubitemid 36987852)
9. Carnaud,C.etal.1999.Cuttingedge:Cross talkbetweencellsoftheinnateimmunesystem:NKTcellsrapidlyactivateNKcells.J. Immunol.163:4647-4650.(Pubitemid29501223)
10. Taniguchi, M. et al. 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21: 483-513. (Pubitemid 37174539)
11. Exley, MA. et al. 2001. A major fraction of human bone marrow lymphocytes are Th2-like CD 1d-reactive T cells that can suppress mixed lymphocyte responses. J. Immunol. 167: 5531-5534.
12. Kenna, T. et al. 2007. CD1 expression and CD1-restricted T cell activity in normal and tumourbearing human liver. Cancer Immunol. Immunother. 56: 563-572. (Pubitemid 46204542)
13. + T cells. J. Immunol. 164: 2009-2015.
14. Brutkiewicz,R.R.2006.CD1dligands:thegood,thebad,andtheugly.J.Immunol.177: 769-775.(Pubitemid44036575)
15. Jahng, A. et al. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD 1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199: 947-957. (Pubitemid 38481086)
16. Van Rhijn, I. et al. 2004. CD 1 d-restricted T cell activation by nonlipidic small molecules. Proc. Natl. Acad. Sci. USA 101: 13578-13583. (Pubitemid 39238445)
17. Wu, D.Y. et al. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198: 173-181. (Pubitemid 36870197)
18. + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl. Acad. Sci. USA 99: 8197-8202.
19. Chang, D.H. et al. 2008. Inflammation-associated lysophospholipids as ligands for CD 1d-restricted T cells in human cancer. Blood 112: 1308-1316.
20. Chung, Y. et al. 2007. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 110: 2013-2019. (Pubitemid 47443916)
21. Berzofsky, JA. & M. Terabe. 2008. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol. Immunother. 57: 1679-1683.
22. Crowe, N.Y., M.J. Smyth & D. I. Godfrey. 2002. Acritical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med 196: 119-127. (Pubitemid 34747317)
23. Toura,I.etal.1999.Cuttingedge: inhibitionofexperimentaltumormetastasisbydendriticcellspulsedwithalpha- galactosylceramide.J.Immunol163:2387-2391.(Pubitemid29399156)
24. + T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99: 1259-1266.
25. Fujii, S. et al. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3: 867-874. (Pubitemid 35049438)
26. Hayakawa, Y. et al. 2003. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA 100: 9464-9469. (Pubitemid 37033951)
27. Hayakawa,Y.etal.2002.IFN-gamma- mediatedinhibitionoftumorangiogenesisbynaturalkillerT-cellligand, alpha-galactosylceramide.Blood100:1728-1733.(Pubitemid34925151)
28. Swann,J.etal.2004.RegulationofantitumourimmunitybyCD1d- restrictedNKTcells.Immunol.Cell.Biol.82:323-331.(Pubitemid38870027)
29. Schmieg, J. et al. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med. 198: 1631-1641. (Pubitemid 37494156)
30. Kitamura, H. et al. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189: 1121-1128. (Pubitemid 29169829)
31. Smyth, M.J et al. 2002. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14: 165-171.
32. Tahir, S.M. et al. 2001. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167: 4046-4050.
33. Metelitsa, L.S. et al. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD 1 d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167: 3114-3122.
34. Dhodapkar, M.V. et al. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197: 1667-1676.
35. Terabe, M. et al. 2005. A nonclassical non-Valpha1 4Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J.Exp. Med. 202: 1627-1633. (Pubitemid 41815868)
36. Smyth, M.J. & D.I. Godfrey. 2000. NKT cells and tumor immunity-a double-edged sword. Nat. Immunol. 1: 459-460.
37. Spanoudakis, E. et al. 2009. Regulation of multiple myeloma survival and progression by CD1d. Blood 113: 2498-2507.
38. Giaccone,G.etal.2002.AphaseIstudyofthenaturalkillerT-cellligandalpha- galactosylceramide(KRN7000)inpatientswithsolidtumors.Clin.CancerRes.8:3702-3709. (Pubitemid35424759)
39. + natural killer T cells using alphagalactosyl ceramide-pulsed dendritic cells. J. Immunol. Methods 272: 147-159.
40. Chang, D.H. et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
41. + subset. J. Exp. Med. 187: 1885-1892.
42. Chang, D.H. et al. 2006. Enhancement of liganddependent activation of human natural killer T cells bylenalidomide: therapeutic implications. Blood 108: 618-621.
43. Song, W. et al. 2008. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin. Cancer Res. 14: 6955-6962.